Good news for some who are looking for GLPs for weight loss, but don’t have type II diabetes.
The Medicare GLP-1 Bridge, a temporary nationwide program run by the Centers for Medicare & Medicaid Services (CMS) that operates from July 1, 2026, through December 31, 2027
If you have Medicare Part D or a Medicare Advantage plan that includes drug coverage.
This program is for those who do not have type II diabetes
Standard Medicare Part D plans cover GLP-1 medications for treating Type 2 diabetes, but federal law currently prohibits them from covering drugs prescribed solely for weight loss. The Bridge program was created specifically to bypass this restriction to provide access for weight management.
To qualify, a doctor must submit a prior authorization proving you meet these clinical criteria:
Age: 18 or older.
BMI Requirements: BMI of 35 or higher. Or a BMI of 30 or higher with specific conditions (e.g., uncontrolled high blood pressure, heart failure, chronic kidney disease).
OR BMI of 27 or higher with other risks (e.g., pre-diabetes, previous heart attack, stroke).
Drug Coverage and Cost
Under the Bridge program, the cost is a flat $50 per monthly supply.
However, there is an important detail regarding Ozempic: Ozempic is the brand name for the drug semaglutide when it is specifically prescribed for Type 2 diabetes. Because the Bridge program only covers GLP-1s prescribed for weight loss, it covers the weight-management branding of these medications.
Instead of Ozempic, your doctor will need to prescribe one of the medications officially covered under the Bridge program:
Wegovy (which contains the exact same active ingredient as Ozempic but is branded and dosed for weight loss), Zepbound (tirzepatide), or Foundayo.
How does a doctor submit a prior authorization for the Medicare GLP-1 Bridge program?
- The Doctor Writes a Specific Prescription: Must include specific coding to avoid misrouting.
The doctor writes the prescription for one of the covered medications, such as Wegovy or Zepbound KwikPen. Crucially, the doctor should include an obesity diagnosis code and specifically write “SEND TO BRIDGE FOR WEIGHT MANAGEMENT” on the prescription. This stops the pharmacy from accidentally billing her regular Part D plan.
- The Pharmacy Triggers an Intentional Rejection:
The pharmacy bills the prescription directly to the Bridge program’s central processor using special routing numbers, not her Part D plan. The system will intentionally reject this initial claim to establish an eligibility record and officially flag that a PA is required. The pharmacy then sends the PA request form to the doctor, typically within 24 to 72 hours.
3.The Doctor Submits the Prior Authorization:
Her doctor submits the PA directly to Humana (the Bridge program’s central processor) via fax or an electronic portal like CoverMyMeds. The doctor must medically attest that the medication is for weight management alongside diet and exercise, verify your qualifying BMI and health conditions, and confirm that you do not have Type 2 diabetes.
- Approval and Refills:Medicare processes the PA within 72 hours. Once approved, the authorization is valid through December 31, 2027 (the end of the temporary program). You will pay a flat $50 copay for each 28- or 30-day refill, and you will not need a new authorization for refills or dose changes as long as you stay on the same medication.
Addenda:
Zepbound (tirzepatide) generally results in significantly greater weight loss than Wegovy (semaglutide). Clinical data shows that Zepbound helps patients lose an average of 20% or more of their body weight, compared to roughly 13% to 15% body weight loss with Wegovy. [1, 2, 3]
Key Differences at a Glance
| Feature |
Zepbound (tirzepatide) |
Wegovy (semaglutide) |
| Average Weight Loss |
~20.2% of body weight (at 72 weeks) |
~13.7% to 15% of body weight (at 68–72 weeks) |
| Hormones Targeted |
Dual Agonist: GLP-1 and GIP |
Single Agonist: GLP-1 only |
| Administration |
Weekly injection |
Weekly injection (and a pill version) |
| Age Approval |
Adults only |
Adults and children ages 12+ |
| Extra Benefits |
Obstructive sleep apnea |
Cardiovascular risk and fatty liver reduction |